RANK

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis

Retrieved on: 
Tuesday, February 20, 2024
Health Canada, Denosumab, RANK, Biosimilar, Safety, FRCPC, Novartis, Patient, Osteoporosis, Generic drug

Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.

Key Points: 
  • Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.
  • Health Canada approval based on robust Phase I and Phase III clinical studies.
  • BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, reference medicine: Prolia*).
  • Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass.

Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Retrieved on: 
Thursday, August 25, 2022
COVID-19, CEO, Safety, Pharmacokinetics, Respiratory disease, Man, Denosumab, Volunteering, GLOBE, Adult, Risk, Patient, Cancer, Biosimilar, SEC, Fracture, Communication, Bone loss, Terminology, Woman, Trial of the century, Partnership, Osteoporosis, BMD, Teva Pharmaceuticals, Autoimmune disease, NASDAQ, DKSH, Adalimumab, Private Securities Litigation Reform Act, Marketing, RANK, Degenerative disease, Goal, Stada Arzneimittel, Bone disease, Forward-looking statement, Generic drug, EU

In 2021, combined net revenues worldwide from sales of Prolia and Xgeva were nearly US$5.3 billion.

Key Points: 
  • In 2021, combined net revenues worldwide from sales of Prolia and Xgeva were nearly US$5.3 billion.
  • We are proud to be able to initiate the confirmatory patient study for AVT03, adding another important milestone in the development of our biosimilars portfolio.
  • A biosimilar to Humira (adalimumab) is already approved in Europe (Hukyndra) and Canada (Simlandi), and three biosimilar candidates including AVT03 have entered or completed confirmatory patient studies.
  • AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia and Xgeva (denosumab).

Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Retrieved on: 
Wednesday, July 20, 2022
Osteoporosis, Interleukin, Goal, Male, Respiratory disease, Cytokine, GLOBE, BLA, TNF, R, Trial of the century, Biosimilar, Woman, Forward-looking statement, Ulcerative colitis, SEC, Denosumab, Vascular endothelial growth factor A, Bone loss, Risk, Marketing, Adult, Safety, COVID-19, Ophthalmology, NASDAQ, Cancer, Ustekinumab, Review, RANK, VEGF, Patient, Psoriasis, Pharmacokinetics, Bone disease, Adalimumab, Man, Terminology, Fracture, Autoimmune disease, Communication, Generic drug, Pharmaceutical industry, Vaccine, EU

The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia in healthy adult male subjects.

Key Points: 
  • The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia in healthy adult male subjects.
  • In 2021, combined net revenues worldwide from sales of Prolia and Xgeva were nearly US$5.3 billion1.
  • In May, Alvotech announced positive topline results from both a confirmatory clinical, safety and efficacy study and from a pharmacokinetic (PK) study for AVT04 (ustekinumab), a proposed biosimilar to Stelara.
  • In July, Alvotech announced the initiation of a confirmatory clinical study for AVT06 (aflibercept), a proposed biosimilar to Eylea.

Global Postmenopausal Osteoporosis Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Health, Pharmaceutical, Patient, News, Osteoporosis, Clinical trial, Discovery, RANK, SOST, Route, Company, Therapy, Teva Pharmaceuticals, II, Eli Lilly and Company, Administration, Immunoglobulin G, Route of administration, III, Dietary supplement, Pharmaceutical industry, Denosumab, Menopause

The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Postmenopausal osteoporosis - Pipeline Insight, 2021 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape.
  • Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of postmenopausal osteoporosis.
  • Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

New Analysis from Global Industry Analysts Reveals Steady Growth for Remote Terminal Unit (RTU) in Smart grid , with the Market to Reach $318.7 Million Worldwide by 2026

Retrieved on: 
Friday, October 22, 2021
Research, Schweitzer Engineering Laboratories, SAN, Remote terminal unit, INC, General Electric Company, Geography, Honeywell, Players, RANK, Intelligence, TOP, Siemens, Marketing, RTU, COVID-19, CAGR, Forecasting, GIA, Schneider Electric, ABB, Renewable energy, Pet

SAN FRANCISCO, Oct. 22, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Remote Terminal Unit (RTU) in Smart grid - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Oct. 22, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Remote Terminal Unit (RTU) in Smart grid - Global Market Trajectory & Analytics" .
  • Geographies:World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
  • The U.S. Market is Estimated at $75.6 Million in 2021, While China is Forecast to Reach $56.7 Million by 2026
    The Remote Terminal Unit (RTU) in Smart grid market in the U.S. is estimated at US$75.6 Million in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

DiFusion’s New ZFUZE Biomaterial Data Beats Titanium in Multiple Studies

Retrieved on: 
Tuesday, October 20, 2020
Biotechnology, Health, Surgery, Medical devices, Branches of biology, Organic compounds, Tissue engineering, Biology, Biomedical engineering, Biomaterial, Biomolecules, Implant, Osteoimmunology, RANK, Polyether ether ketone

DiFusion Inc, unveiled groundbreaking Osteoimmunology data at the North American Spine Society 2020 Annual Meeting demonstrating the superiority of the new biomaterial ZFUZE over Nano-Surfaced Titanium and conventional PEEK materials.

Key Points: 
  • DiFusion Inc, unveiled groundbreaking Osteoimmunology data at the North American Spine Society 2020 Annual Meeting demonstrating the superiority of the new biomaterial ZFUZE over Nano-Surfaced Titanium and conventional PEEK materials.
  • ZFUZE is the first biomaterial specifically engineered to interact with the human immune system such that the human immune system does not attack it as a foreign body.
  • ZFUZE outperformed Nano-surfaced Titanium and conventional PEEK on a statistically significant basis across all three studies.
  • The Effects of Biomaterial Implant Wear Debris on Osteoblast: Li Zhang, Kristian Welle, Christof Burger, Frank Shildberg.

Innovent Receives IND Approval to Initiate Clinical Trials in China with its anti-OX40 Agonistic Antibody IBI101 and its anti-RANKL Antibody IBI307

Retrieved on: 
Thursday, July 26, 2018
Immune system, Immunology, T cells, CD134, RANKL, RTT, RANK, Denosumab, Osteoporosis

Innovent's IBI101, is the first OX40-targeted molecule to receive IND approval in China.

Key Points: 
  • Innovent's IBI101, is the first OX40-targeted molecule to receive IND approval in China.
  • Innovent will be among one of a few companies pursuing the development of OX40 agonists in early stage clinical trials globally.
  • IBI307 is an anti-RANKL antibody under development for the treatment of osteoporosis and lytic bone lesions associated with cancer metastasis.
  • Innovent intends to pursue simultaneous development of this asset in China as well as outside of China.